Ocrelizumab in pediatric multiple sclerosis.
暂无分享,去创建一个
[1] S. Cohan,et al. Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study , 2021, BMJ Neurology Open.
[2] H. Weiner,et al. Improved relapse recovery in paediatric compared to adult multiple sclerosis. , 2020, Brain : a journal of neurology.
[3] A. Bar-Or,et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations , 2020, Multiple sclerosis.
[4] E. Waubant,et al. Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis , 2020, Annals of neurology.
[5] M. Moodley,et al. Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis , 2019, Current Treatment Options in Neurology.
[6] R. Greil,et al. Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination , 2019, Glia.
[7] J. Lechner-Scott,et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis , 2019, JAMA.
[8] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[9] A. Traboulsee,et al. Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.
[10] B. Weinshenker,et al. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis , 2015, Neurology.
[11] H. Weiner,et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.
[12] Carsten Lukas,et al. Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model , 2015, Therapeutic advances in neurological disorders.
[13] Y. Ben-Shlomo,et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[14] T. Chitnis,et al. Pathogenesis of Pediatric Multiple Sclerosis , 2012, Journal of child neurology.
[15] A. Ghezzi,et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis , 2012, Multiple sclerosis.
[16] M Ramanathan,et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. , 2009, Brain : a journal of neurology.
[17] D. Paty,et al. Early onset multiple sclerosis: A longitudinal study , 2002, Neurology.
[18] P. Huppke,et al. Therapy of highly active pediatric multiple sclerosis , 2019, Multiple sclerosis.
[19] P. Vermersch,et al. Natural history of multiple sclerosis with childhood onset. , 2007, The New England journal of medicine.
[20] Frcp,et al. Pediatric multiple sclerosis Escalation and emerging treatments , 2022 .
[21] A. Ghezzi,et al. Pediatric multiple sclerosis Clinical features and outcome , 2022 .